Management of Obstructive Pyelonephritis with Sepsis

Immediate Priorities

• The American College of Radiology recommends emergent urinary tract decompression with either retrograde ureteral stenting or percutaneous nephrostomy (PCN), along with immediate broad-spectrum intravenous antibiotics, as antibiotics alone are insufficient in treating acute obstructive pyelonephritis 1, 2
• PCN is usually the most appropriate intervention for patients presenting with obstructive pyelonephritis who appear septic with hypotension, fever, and leukocytosis, with a patient survival rate of 92% compared to 60% for medical therapy without decompression 1, 2
• Urinary tract decompression can be lifesaving in patients with fever, tachycardia, significant pyuria, and obstructing stone, with hospitalization times shorter in the nephrostomy group compared to other interventions 2

Alternative Interventions

• Retrograde ureteral stenting is an equivalent alternative to PCN for obstructive pyelonephritis, with decreased duration of hospital stay and ICU admission rate compared to PCN, although prolonged guidewire and catheter manipulation can increase the incidence of urosepsis 1, 2, 3

Antibiotic Therapy

• The American College of Radiology recommends third-generation cephalosporin (ceftriaxone) as empiric coverage, demonstrating superiority over fluoroquinolone (ciprofloxacin) in both clinical and microbiological cure rates for obstructive pyelonephritis 2
• Preprocedural antibiotics are recommended when urosepsis is suspected or known to be present, and PCN can yield important bacteriological information to alter antibiotic treatment regimens 2

Diagnostic Interpretation

• Urinalysis findings, including leukocytes, nitrite, and WBC, are highly suggestive of UTI, with nitrite having 98% specificity for UTI, although sensitivity is only 49% 4, 5
• The combination of leukocyte esterase OR nitrite has 88% sensitivity and 79% specificity for UTI, and WBC sensitivity and specificity are 62.7% and 100% respectively 5

Clinical Context

• The presence of fever, tachycardia, and signs of obstruction with infection meets criteria for obstructive pyelonephritis requiring urgent intervention, with pyuria or positive leukocyte esterase confirming the need for urine culture and antimicrobial therapy 1, 2, 4

Common Pitfalls to Avoid

• Antibiotics alone are insufficient in treating acute obstructive pyelonephritis, and decompression is essential, with medical therapy without decompression having only 60% survival compared to 92% with PCN 2
• Postprocedural bacteremia and sepsis are common when infected urinary tracts are drained, and close monitoring for worsening sepsis is required immediately intraprocedure and postprocedure 2, 3

Definitive Stone Management

• Definitive stone treatment should be delayed until sepsis is resolved, and plan for stent removal once underlying pathology is definitively treated and infection cleared 6

Management of Obstructive Pyelonephritis

Antibiotic Management

• The American College of Radiology recommends ceftriaxone 1-2g IV daily as first-line empiric therapy for obstructive pyelonephritis, due to its superiority over fluoroquinolones in clinical and microbiological cure rates 7
• Ceftriaxone demonstrates effectiveness in covering expected uropathogens, including Klebsiella, which commonly colonizes ureteral stents 8, 7

Urinary Decompression Strategy

• The Journal of the American College of Radiology suggests that retrograde ureteral stent exchange or percutaneous nephrostomy (PCN) are equivalent options for emergent decompression, with PCN providing larger tube decompression for pyonephrosis 9

Prevention of Recurrent Infection

• The Ca-A Cancer Journal for Clinicians recommends scheduling routine stent exchanges every 3 months to prevent recurrent infection, as the main risk factor for device-related urinary infections is the length of time the device remains in place 8, 7
• Targeted prophylaxis based on prior culture results, such as ceftriaxone or ampicillin-sulbactam, reduces sepsis complications from 50% to 9% 7

Management of Obstructive Pyelonephritis

Clinical Justification

• A high white blood cell count (>14,000 cells/mm³) indicates a high probability of underlying bacterial infection, even in the absence of fever, with a likelihood ratio of 3.7 for documented bacterial infection, according to the Infectious Diseases Society of America 10, 11
• The absence of fever does not rule out a severe infection, particularly in patients with urinary obstruction and prosthetic material, as stated by the Infectious Diseases Society of America 10
• Costovertebral pain in this context represents acute non-obstructive or obstructive pyelonephritis, defined by pain and tenderness of the costovertebral angle, often with fever (but not always), as described in Clinical Infectious Diseases 12

Risk Assessment

• Urinary decompression may be vital in patients with pyonephrosis (hydronephrosis with infection) on a single kidney, with a survival rate of 92% compared to 60% with medical treatment alone without decompression, according to the American College of Radiology 13
• The duration of hospitalization is shorter in the percutaneous nephrostomy group, as reported by the American College of Radiology 13

Diagnostic Evaluation

• Urine culture with antibiogram (after catheter change if applicable) is recommended by the Infectious Diseases Society of America 10
• Blood cultures are recommended if urosepsis is suspected, as stated by the Infectious Diseases Society of America 10
• Gram stain on uncentrifuged urine is recommended if urosepsis is suspected, according to the Infectious Diseases Society of America 10

Treatment

• The American College of Radiology recommends ceftriaxone 1-2g IV per day as empirical treatment, demonstrating superiority over fluoroquinolones in terms of clinical and microbiological cure rates 13
• Antibiotic prophylaxis based on previous culture results (ceftriaxone or ampicillin-sulbactam) reduces septic complications from 50% to 9%, as reported by the American College of Radiology 13

Management of Ureteric Stenting in Active Urinary Tract Infection

Indications for Stent Placement in the Setting of Active Infection

• In patients with an obstructed urinary system and a concurrent urinary tract infection, emergent ureteric stent placement is recommended because decompression is lifesaving and antibiotics alone are insufficient. 14, 15
• Retrograde ureteral stenting is a first‑line treatment for obstructive pyelonephritis when combined with antibiotic therapy, providing efficacy comparable to percutaneous nephrostomy (PCN). 14, 15
• Decompression of pyonephrosis improves survival to approximately 92 % versus 60 % with medical therapy alone. 14, 15

Choice of Drainage Modality (Stent vs. PCN)

• Both retrograde ureteral stenting and PCN are acceptable options for emergent urinary drainage; the selection should be based on local practice patterns, patient stability, and comorbid conditions. 14, 15
• PCN may be preferred in hemodynamically unstable or septic patients with hypotension because it provides a larger‑diameter drainage tract and demonstrates higher technical success in certain scenarios. 14, 15

Antibiotic Management Prior to Decompression

• Empiric broad‑spectrum intravenous ceftriaxone is recommended as first‑line therapy before any instrumentation, as it has shown superior clinical and microbiological cure rates compared with fluoroquinolones for obstructive pyelonephritis. 14, 15

Procedural Considerations and Microbiological Sampling

• Blood and urine cultures should be obtained before initiating antibiotics to allow targeted therapy.
• PCN yields more comprehensive bacteriological information than bladder urine cultures alone, enhancing pathogen identification. 14, 15
• Emergent decompression (either stent or PCN) must not be delayed awaiting infection clearance; the urgency is dictated by the presence of sepsis signs (fever, hypotension, tachycardia). 14, 15

Post‑Procedural Risks and Monitoring

• Post‑procedural bacteremia and sepsis are common after draining infected urinary tracts; continuous intraprocedural and post‑procedural monitoring is essential. 14, 15

Management of Non‑Obstructive Urinary Tract Infections

• In uncomplicated urinary tract infections without obstruction, routine ureteric stent placement is not indicated, as it adds unnecessary morbidity. 16
• Internal double‑J ureteral stents carry an infection rate of roughly 11 % and are especially prone to bacterial colonization and biofilm formation. 16

Management of Acute Obstructive Pyelonephritis with Urinary Stone in Adult Males

Immediate Assessment and Diagnosis

Urgent Urinary Decompression

Empiric Antibiotic Therapy

Timing of Definitive Stone Management (Delayed)

Peri‑operative Antibiotic Prophylaxis

Special Considerations for Infection Stones

Critical Pitfalls to Avoid

Management of Obstructive Pyelonephritis with Ureteral Stone

Urinary Decompression

• Emergent urinary decompression is required for any obstructed infected kidney, and can be achieved either by retrograde ureteral stenting or percutaneous nephrostomy, with the choice guided by patient stability and institutional expertise. 21

Timing of Definitive Stone Treatment

• Definitive stone removal should be postponed until the infection has been fully treated and sepsis has resolved, typically after completing a full course of intravenous antibiotics. 21

Medical Expulsive Therapy (MET)

• Alpha‑blocker therapy (e.g., tamsulosin) is appropriate for uncomplicated ureteral stones larger than 5 mm, but it is contraindicated when an active urinary tract infection is present; drainage, not expectant management, is required in that setting. 21

Antibiotic Management Post‑Decompression

• After urinary drainage, antimicrobial therapy must be tailored to the results of blood and urine cultures, adjusting agents according to identified pathogens and sensitivities. 21

Management of Post‑Stent Removal Complications with Obstructive Infection

Risk Assessment

• Patients who have undergone recent ureteral stent manipulation and present with impaired renal function (e.g., estimated GFR ≈ 46 mL/min/1.73 m²) are at high suspicion for obstruction‑related or infection‑related acute kidney injury. 22
• The combination of leukocytosis and recent stent manipulation confers a high risk for developing urosepsis. 23

Complication Rates of Stent Removal

• Stent migration is reported in 5–8 % of cases after removal. 22
• Ureteral injury occurs in approximately 6 % of patients following stent removal. 22

Immediate Therapeutic Recommendations

• Pre‑procedural antibiotics should be administered when urosepsis is suspected, because bacteremia and sepsis frequently follow drainage of infected urinary tracts. 23
• Percutaneous nephrostomy (PCN) provides superior drainage for pyonephrosis compared with internal stents, achieving a patient survival of ≈ 92 % versus ≈ 60 % with medical therapy alone. 23
• Retrograde ureteral stenting is an acceptable alternative for urinary decompression in hemodynamically stable patients; however, prolonged guide‑wire manipulation may increase the risk of urosepsis. 23
• Continuous monitoring for worsening sepsis during and after drainage procedures is essential, as bacteremia is common when infected urinary tracts are drained. 23